PHARMAMAR HA ACTUALIZADO FASE III LAGOON LURBINECTEDIN Y SE RETRASA SU CONCLUSIÓN HASTA ABRIL 2026. : Yondelis // EEUU /// FDA . Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma : Dados los Resultados Positivos Obtenidos en los Ensayos Clínicos Múltiples, Van Tine Espera que la FDA " Apruebe Yondelis " para el Tratamiento de Liposarcomas y Leiomiosarcomas .

04 junio 2015

Yondelis // EEUU /// FDA . Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma : Dados los Resultados Positivos Obtenidos en los Ensayos Clínicos Múltiples, Van Tine Espera que la FDA " Apruebe Yondelis " para el Tratamiento de Liposarcomas y Leiomiosarcomas .

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma .

Brian A. Van Tine, MD, PhD
Published Online: Wednesday, June 3, 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

Trabectedin has been available for over a decade outside of the United States for the treatment of leiomyosarcoma and liposarcoma. It is available at compassionate use centers throughout the United States, but is not currently FDA approved.

It is an exciting drug that has excellent progression-free survival and response rates in leiomyosarcoma and liposarcoma patients, says Van Tine.

Considering its positive results in multiple clinical trials, Van Tine hopes that the FDA will approve the drug for leiomyosarcoma and liposarcoma in the near future.